Functional spectrum of USP7 pathogenic variants in Hao–Fountain syndrome: Insights into the enzyme’s activity, stability, and allosteric modulation

E Emilie J. Korchak (Department of Molecular Biology and Biophysics, University of Connecticut) M Mona Sharafi (Department of Cancer Biology, Dana-Farber Cancer Institute) I Isabella Jaen Maisonet (Department of Cancer Biology, Dana-Farber Cancer Institute) A Andres Salazar-Chaparro (Department of Cancer Biology, Dana-Farber Cancer Institute) I Irina V. Semenova (Department of Molecular Biology and Biophysics, University of Connecticut) H Hamza Khan A Alison L. O’Neil (Department of Chemistry, Neuroscience and Behavior Program, Wesleyan University) P Pilar Caro (Institute of Human Genetics, Heidelberg University) C Christian P. Schaaf (Institute of Human Genetics, Heidelberg University) S Sara J. Buhrlage (Department of Cancer Biology, Dana-Farber Cancer Institute) I Irina Bezsonova

Abstract

Hao–Fountain syndrome is a rare neurodevelopmental disorder caused by mutations in the deubiquitinating enzyme Ubiquitin-Specific Protease 7 (USP7). Due to the novelty of the disease and its poorly understood molecular mechanisms, treatments for the syndrome are currently lacking. This study examines the effects of 11 patient-derived variants located within the catalytic domain of USP7, focusing on their impact on the enzyme’s activity, thermodynamic stability, and substrate recognition. Our findings reveal a spectrum of functional consequences, ranging from complete inactivation to hyperactivation of USP7. Notably, we identify a specific subset of pathogenic variants whose catalytic activity can be significantly boosted using an allosteric activator, MS-8. These results provide insight into USP7 malfunction in Hao–Fountain syndrome–linked variants and pave the way for improved prognostic approaches and targeted treatments in the future.

Article Details

Volume / Issue Vol. 122, Issue 39
Published September 30, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (11)

E

Emilie J. Korchak

Department of Molecular Biology and Biophysics, University of Connecticut

M

Mona Sharafi

Department of Cancer Biology, Dana-Farber Cancer Institute

I

Isabella Jaen Maisonet

Department of Cancer Biology, Dana-Farber Cancer Institute

A

Andres Salazar-Chaparro

Department of Cancer Biology, Dana-Farber Cancer Institute

I

Irina V. Semenova

Department of Molecular Biology and Biophysics, University of Connecticut

H

Hamza Khan

A

Alison L. O’Neil

Department of Chemistry, Neuroscience and Behavior Program, Wesleyan University

P

Pilar Caro

Institute of Human Genetics, Heidelberg University

C

Christian P. Schaaf

Institute of Human Genetics, Heidelberg University

S

Sara J. Buhrlage

Department of Cancer Biology, Dana-Farber Cancer Institute

I

Irina Bezsonova